您的位置：
首页
>
农业专利
>
详情页
TREATMENT OF A METABOLIC DISORDER
专利权人:
Andrew Ian Bayliffe
发明人:
Andrew Ian Bayliffe
申请号：
US13577931
公开号：
US20120308564A1
申请日:
2011.02.07
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The present disclosure relates to the field of metabolic disorders, including type II diabetes and obesity. Specifically, the disclosure relates to methods of treating and/or preventing a metabolic disorder with an IL-18 antagonist, in particular an anti-IL-18 antigen binding protein, in particular an anti-IL-18 antibody.
来源网站：
中国工程科技知识中心
来源网址：
http://www.ckcest.cn/home/
相关专利
NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3BETA-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVERS DISEASES AND ATHEROSCLEROSIS
NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3BETA-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVERS DISEASES AND ATHEROSCLEROSIS
NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3BETA-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVERS DISEASES AND ATHEROSCLEROSIS
A NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3.BETA.-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVER DISEASES AND ATHEROSCLEROSIS
A NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3BETA-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVER DISEASES AND ATHEROSCLEROSIS
